Consistent with this, our group previously demonstrated a progressive decrease in TFAM mRNA levels with increasing astrocytoma malignancy, reaching the lowest levels in GBM, particularly in the MS and GPM subtypes—those associated with the worst prognosis [18]. This evidence concerns the gene TFAM and astrocytoma (excluding glioblastoma).